Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preemptive Genotyping of CYP2C8 and CYP2C9 Allelic Variants Involved in NSAIDs Metabolism for Sickle Cell Disease Pain Management.

Clinical and translational science - 1 Aug 2015

Jaja Cheedy, Bowman Latanya, Wells Leigh, Patel Niren, Xu Hongyan, Lyon Matt, Kutlar Abdullah

Abstract excerpt

Interindividual variability in analgesic effects of nonsteroidal anti-inflammatory drugs prescribed for sickle cell disease (SCD) pain is attributed to polymorphisms in the CYP2C8 and CYP2C9 enzymes. We described CYP2C8 and CYP2C9 genotype/phenotype profiles and frequency of emergency department (ED) visits for pain management in an African American SCD patient cohort. DNA from 165 unrelated patients was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Alleles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anemia, Sickle Cell

Share to Anti-Inflammatory Agents, Non-Steroidal

Share to Cytochrome P-450 CYP2C8

Share to Cytochrome P-450 CYP2C9

Share to Genotype

Share to Pain Management

Source

Open in PubMed Open full text

Identifiers

PMID: 25640739
DOI: 10.1111/cts.12260
PMCID: PMC4522406

Genes

CYP2C9
CYP2C8
SCD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preemptive Genotyping of CYP2C8 and CYP2C9 Allelic Variants Involved in NSAIDs Metabolism for Sickle Cell Disease Pain Management.PMID 25640739Read ↗

CYP2C9 allelic variants and frequencies in a pediatric sickle cell disease cohort: implications for NSAIDs pharmacotherapy.Semantic proximity Read ↗

Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in African American children with sickle cell disease.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.Semantic proximity Read ↗

Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management.Semantic proximity Read ↗

Pharmacogenetic Testing for Analgesic Adverse Effects: Pediatric Case Series.Semantic proximity Read ↗

Pharmacogenetics of Pain Management in Zimbabwean Patients With Sickle Cell DiseaseSemantic proximity Read ↗

Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients.Semantic proximity Read ↗

Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.Semantic proximity Read ↗

Genetic Determinants of Analgesic Responsiveness: A Focus on CYP2D6 and COMT Polymorphisms in Chronic Pain.Semantic proximity Read ↗

Pharmacogenetics: Using Genetic Information to Guide Drug Therapy.Semantic proximity Read ↗

CYP2D6 Phenotypes and Emergency Department Visits Among Patients Receiving Opioid Treatment.Semantic proximity Read ↗

Fundamental Considerations for GeneticallyGuided Pain Management with Opioids Based on CYP2D6 and OPRM1 PolymorphismsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.